Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib

Ann Hematol. 2015 Oct;94(10):1749-51. doi: 10.1007/s00277-015-2429-5. Epub 2015 Jun 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Humans
  • Janus Kinases / antagonists & inhibitors*
  • Male
  • Nitriles
  • Polycythemia / diagnosis*
  • Polycythemia / drug therapy*
  • Primary Myelofibrosis / diagnosis*
  • Primary Myelofibrosis / drug therapy*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Treatment Outcome

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinases